Figure 1

A general strategy to design ML prodrugs. The scaffold of PSA-cleavable prodrug with the highlighted specific building blocks: (1) albumin, (2) albumin binding moiety – EMC, (3) PSA-specific sequence, (4) selected linker, and (5) ML inhibitor. The chemical structures of linkers and the amino acid sequences of the ligands used in this study.